Ann: Maiden purchase order received for Prizma device in Italy, page-3

Medical device and telehealth company G Medical Innovations Holdings Ltd (ASX: GMV) (“G Medical” or
“Company”) is pleased to report that it has secured a maiden purchase order (“PO”) in Italy for an initial 1,000
Prizma devices from European telemedicine provider Meditel srl (“Meditel”). Pricing and product information for
the Prizma in Italy is available at www.mediwebnet.it.
The PO is a pleasing development for GMV especially given the Company only established a distribution
agreement with Meditel in February this year (ASX announcement 6 February 2020) and had the Prizma
registered on Italian Health Ministry Database of medical products in April (ASX announcement 6 April 2020).
This is the first PO for the Prizma in Italy and will greatly assist Meditel and GMV ramp-up customer demand as it
will become a useful reference point for more consumers and other potential distributors.
G Medical has undertaken considerable work to ensure the Prizma device is ready for sale in Italy including
translating all relevant smartphone apps associated with the device; translating and printing relevant packaging;
providing documentation to respective regulatory bodies in Italy; ongoing education initiatives with Meditel
personnel; and ensuring contract manufacturers and logistics providers have product at the ready to fulfil
consumer orders.
The first batch of Prizma devices have been delivered from Israel, and as such, Meditel is now fully equipped to
process first consumer sales through its online store which is now live. Significant groundwork has been
undertaken to ensure sales can be scaled up rapidly. As well as direct-to-consumer sales, Meditel and GMV are
building commercial sales channels targeting physicians, healthcare professionals and medical organisations.
Meditel has an active marketing and business development program to underpin sales.
CEO and Executive Director Dr Yacov Geva said: “This first purchase order of 1,000 devices is pleasing, and while
relatively modest in size, it marks the first step in G Medical establishing a sales base for the Prizma in Europe. We
are confident that more POs will surely follow. In just four months, we have moved from an initial distribution
agreement to a first order. This is indeed a great achievement and a good first start for us in Italy.
“We are intent on fully capitalising on the market opportunity with Meditel by building both direct-to-consumer
and commercial sales channels. First Prizma sales in Italy further diversifies our revenue streams and adds to the
steady revenue we generate from our independent diagnostic testing facility (IDTF) operations in the USA.
“We look forward to reporting on more Prizma sales in Italy and other markets as our other distributors start to
ramp up sales programs.”